Sanofi Consumer Healthcare Q2 FY26: PAT rises 13 percent YoY to Rs 688 mn
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi Consumer Healthcare India reported Q2 FY26 revenue of Rs 2,357 mn, up about 7 percent YoY. Profit after tax rose 13 percent to Rs 688 mn; PBT up 16 percent to Rs 919 mn. Half year revenue grew 18 percent to Rs 4,649 mn with PAT up 23 percent to Rs 1,366 mn. Domestic sales grew 12 percent in Q2 aided by relaunch of recalled products; export sales fell 9 percent. Cash and equivalents stood at Rs 4,902 mn. Statutory auditor changed to Price Waterhouse from prior firm; limited review is clean.
Strong profit growth with healthy cash balance and zero debt; auditor change noted but review report is unmodified.